HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$38.53

Market cap

$4.89B

P/E Ratio

18.09

Dividend/share

N/A

EPS

$2.13

Enterprise value

$6.27B

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in ...

Highlights
HALO's EPS is up by 44% year-on-year and by 12% since the previous quarter
HALO's net income is up by 39% year-on-year and by 11% since the previous quarter
Halozyme Therapeutics's quick ratio has decreased by 17% from the previous quarter but it has increased by 12% YoY
The company's equity has shrunk by 66% QoQ and by 51% YoY
Halozyme Therapeutics's gross margin has decreased by 2.7% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO
Market
Shares outstanding
126.82M
Market cap
$4.89B
Enterprise value
$6.27B
Valuations
Price to earnings (P/E)
18.09
Price to book (P/B)
60.73
Price to sales (P/S)
6.13
EV/EBIT
17.07
EV/EBITDA
13.87
EV/Sales
7.56
Earnings
Revenue
$829.25M
EBIT
$367.09M
EBITDA
$451.95M
Free cash flow
$373.28M
Per share
EPS
$2.13
Free cash flow per share
$2.83
Book value per share
$0.63
Revenue per share
$6.29
TBVPS
$6.39
Balance sheet
Total assets
$1.73B
Total liabilities
$1.65B
Debt
$1.5B
Equity
$83.81M
Working capital
$633.93M
Liquidity
Debt to equity
17.89
Current ratio
6.64
Quick ratio
5.07
Net debt/EBITDA
3.06
Margins
EBITDA margin
54.5%
Gross margin
76.8%
Net margin
34%
Operating margin
40.7%
Efficiency
Return on assets
15.8%
Return on equity
204.8%
Return on invested capital
17.7%
Return on capital employed
22.6%
Return on sales
44.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
-1.51%
1 week
1.9%
1 month
-4.68%
1 year
14.78%
YTD
4.25%
QTD
-5.29%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$829.25M
Gross profit
$636.89M
Operating income
$337.57M
Net income
$281.59M
Gross margin
76.8%
Net margin
34%
HALO's net income is up by 39% year-on-year and by 11% since the previous quarter
The company's operating income rose by 26% YoY and by 9% QoQ
The company's revenue rose by 26% YoY and by 6% QoQ
HALO's gross profit is up by 22% YoY and by 6% QoQ

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
18.09
P/B
60.73
P/S
6.13
EV/EBIT
17.07
EV/EBITDA
13.87
EV/Sales
7.56
HALO's EPS is up by 44% year-on-year and by 12% since the previous quarter
The stock's price to earnings (P/E) is 15% less than its last 4 quarters average of 21.7
The company's equity has shrunk by 66% QoQ and by 51% YoY
HALO's price to book (P/B) is 63% higher than its 5-year quarterly average of 37.8 and 31% higher than its last 4 quarters average of 47.1
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 12.7 and 2.8% lower than the last 4 quarters average of 6.4
The company's revenue rose by 26% YoY and by 6% QoQ

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has soared by 108% YoY and by 28% from the previous quarter
Halozyme Therapeutics's return on assets has increased by 30% YoY and by 13% QoQ
HALO's return on invested capital is up by 23% year-on-year and by 8% since the previous quarter
HALO's return on sales is up by 10% year-on-year and by 3% since the previous quarter

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 5% higher than its total liabilities
The company's current ratio rose by 18% YoY but it fell by 13% QoQ
Halozyme Therapeutics's quick ratio has decreased by 17% from the previous quarter but it has increased by 12% YoY
Halozyme Therapeutics's debt to equity has soared by 198% from the previous quarter and by 102% YoY
The company's equity has shrunk by 66% QoQ and by 51% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.